サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1559732

ループス治療薬の世界市場

Lupus Therapeutics

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.81円
ループス治療薬の世界市場
出版日: 2024年09月24日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ループス治療薬の世界市場は2030年までに75億米ドルに到達

2023年に42億米ドルと推定されるループス治療薬の世界市場は、分析期間2023-2030年にCAGR 8.6%で成長し、2030年には75億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗炎症薬は、CAGR 8.1％を記録し、分析期間終了時には27億米ドルに達すると予測されます。副腎皮質ステロイド薬セグメントの成長率は、分析期間中CAGR 8.3％と推定されます。

米国市場は12億米ドルと推定、中国はCAGR 8.2％で成長予測

米国のループス治療薬市場は2023年に12億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.9%と7.1%と予測されています。欧州では、ドイツがCAGR約7.1%で成長すると予測されています。

世界のループス治療薬市場- 主要動向と促進要因のまとめ

今日のループス治療における課題と機会とは？

狼瘡は、免疫系が自己の組織を攻撃することを特徴とする慢性自己免疫疾患であり、軽度の皮疹から重度の腎障害に至るまで複雑で多様な症状を呈するため、治療には大きな課題があります。従来のループス治療は、コルチコステロイドや抗マラリア薬などの非特異的な免疫抑制剤が中心でした。しかし、この疾患の根底にある生物学的経路の解明が進むにつれて、広範な免疫抑制を行わずに特定の免疫系成分を調節することを目的とした標的療法の可能性が開けてきました。これらの進歩は、ループス治療における個別化医療へのシフトを意味し、患者特有の病状や遺伝子プロファイルに焦点を当てることで、治療効果と患者の生活の質の両方を向上させる。

新しいテクノロジーはどのようにループス治療に革命をもたらしているのか？

バイオテクノロジーと薬理学的進歩の統合は、ループス治療に革命をもたらし始めています。特定の免疫系分子を標的として特別に設計された生物学的製剤の開発は、従来の治療法に反応しない患者に新たな希望をもたらしています。例えば、炎症の発症に重要な役割を果たす免疫系タンパク質を阻害するモノクローナル抗体は、ループスの症状の重篤度を軽減する効果が期待されています。さらに、ゲノミクスの進歩により、疾患に関連する遺伝子マーカーの同定が容易になり、より早期の診断や、よりオーダーメイドの治療戦略につながる可能性が出てきました。このような技術革新は、ループス治療の精度を高めるだけでなく、従来の治療法にしばしば見られる重篤な副作用の発生を抑えることにも役立っています。

患者の支持と意識向上はループス治療薬市場にどのような影響を与えているか？

ループス治療薬市場を変化させる上で、認知度の向上と患者アドボカシーが重要な役割を果たしています。患者支援団体により、狼瘡に対する社会的・医学的理解が深まったことで、効果的な病気の管理に不可欠な早期診断と治療介入が行われるようになりました。これらの団体はまた、より多くの研究資金と、新しい治療法の開発と利用しやすさを支援する、より良い医療政策の推進にも貢献しています。さらに、世界のヘルスリテラシーの向上により、患者は治療方針の決定に積極的に参加できるようになり、より新しく、より毒性が低く、より効果的な治療薬への需要が高まっています。ループス治療薬市場におけるこのような患者中心の治療へのシフトは、転帰を改善するだけでなく、医薬品開発の優先順位やヘルスケア慣行にも影響を及ぼしています。

ループス治療薬市場の成長はいくつかの要因によってもたらされる

ループス治療薬市場の成長は、疾患の理解を深める医学研究の進歩、遺伝子検査の開発、新薬の導入など、いくつかの要因によってもたらされます。研究開発への投資が増加したことで、免疫反応に関与する特定の経路を標的とする新薬が登場し、従来の治療に代わる副作用の少ない治療法が提供されるようになった。さらに、FDAのファスト・トラックや画期的治療薬の指定など、医薬品開発に対する規制当局の支援は、有望なループス治療薬の承認プロセスを加速させ、その商業的可能性と市場参入を高めています。より良いヘルスケアを求める患者の支持の高まりも、革新的な治療に対する需要を刺激し、この分野への継続的な投資と関心を確実なものにしています。これらの力学が相まって、市場は大規模な成長と変革に向かっており、ループス治療の新たな選択肢の時代が到来すると期待されています。

調査対象企業の例（全17件）

  • Bayer AG, Pharmaceuticals
  • Better Therapeutics
  • Biogen, Inc.
  • Biomix Network Ltd.
  • Bristol-Myers Squibb Company
  • Equillium
  • Merck KGaA
  • The NIAID Vaccine Research Center
  • The Peter Doherty Institute for Infection and Immunity

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP13122

Global Lupus Therapeutics Market to Reach US$7.5 Billion by 2030

The global market for Lupus Therapeutics estimated at US$4.2 Billion in the year 2023, is expected to reach US$7.5 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2023-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 8.2% CAGR

The Lupus Therapeutics market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.

Global Lupus Therapeutics Market - Key Trends & Drivers Summarized

What Challenges and Opportunities Exist in Lupus Treatment Today?

Lupus, a chronic autoimmune disease characterized by the immune system attacking its own tissues, presents significant treatment challenges due to its complex and varied symptoms, ranging from mild skin rashes to severe kidney damage. Traditional lupus therapies have largely revolved around non-specific immunosuppressants, such as corticosteroids and antimalarial drugs, which can have wide-ranging side effects and vary in effectiveness. However, the growing understanding of the disease's underlying biological pathways has opened up opportunities for targeted therapies, which aim to modulate specific immune system components without broad immunosuppression. These advancements represent a shift towards more personalized medicine in lupus treatment, focusing on patient-specific disease manifestations and genetic profiles, improving both treatment efficacy and quality of life for patients.

How Are New Technologies Revolutionizing Lupus Treatment?

The integration of biotechnology and pharmacological advancements has begun to revolutionize lupus treatment. The development of biologic drugs, specifically designed to target particular immune system molecules, has provided new hope for patients who do not respond to conventional therapies. For instance, monoclonal antibodies that inhibit immune system proteins, which are pivotal in the development of inflammation, have shown promise in reducing the severity of lupus symptoms. Additionally, advancements in genomics have facilitated the identification of genetic markers associated with the disease, potentially leading to earlier diagnosis and more tailored treatment strategies. These technological innovations not only enhance the precision of lupus therapies but also help in reducing the occurrence of severe side effects that are often associated with traditional treatment options.

What Impact Does Patient Advocacy and Awareness Have on the Lupus Therapeutics Market?

Increased awareness and patient advocacy are playing critical roles in transforming the lupus therapeutics market. Enhanced public and medical understanding of lupus, driven by patient advocacy groups, has led to earlier diagnosis and treatment interventions, which are crucial in managing the disease effectively. These groups have also been instrumental in pushing for more research funding and better healthcare policies that support the development and accessibility of new therapies. Additionally, the global rise in health literacy has empowered patients to actively participate in their treatment decisions, increasing demand for newer, less toxic, and more effective medications. This shift towards patient-centered care in the lupus therapeutics market is not only improving outcomes but is also influencing drug development priorities and healthcare practices.

Growth in the Lupus Therapeutics Market Is Driven by Several Factors

The growth in the lupus therapeutics market is driven by several factors, including advances in medical research that enhance understanding of the disease, developments in genetic testing, and the introduction of novel medications. Increased investment in research and development has led to the emergence of new drugs that target specific pathways involved in the immune response, offering alternatives to traditional treatments with fewer side effects. Furthermore, regulatory support for drug development, such as the FDA’s fast track and breakthrough therapy designations, accelerates the approval process for promising lupus treatments, enhancing their commercial viability and market entry. The growing patient advocacy for better healthcare solutions also stimulates demand for innovative treatments, ensuring continued investment and interest in this field. Together, these dynamics underscore a market geared towards extensive growth and transformation, promising a new era of options for lupus management.

Select Competitors (Total 17 Featured) -

  • Bayer AG, Pharmaceuticals
  • Better Therapeutics
  • Biogen, Inc.
  • Biomix Network Ltd.
  • Bristol-Myers Squibb Company
  • Equillium
  • Merck KGaA
  • The NIAID Vaccine Research Center
  • The Peter Doherty Institute for Infection and Immunity

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Lupus Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Lupus Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Lupus Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Lupus Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Immunosuppressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Immunosuppressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Immunosuppressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Antimalarial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Antimalarial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Antimalarial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for BLyS-Specific Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for BLyS-Specific Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for BLyS-Specific Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Biologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Biologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Biologicals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 25: World Lupus Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Lupus Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Lupus Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Lupus Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: France Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: France 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 47: Germany Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Germany Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Germany 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Italy Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Italy 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 53: UK Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: UK Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: UK 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Rest of World Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Rest of World 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION